Quick Answer
Immunocore Holdings plc reported R&D Expense of $274.87 million for fiscal year 2025.
Immunocore Holdings plc R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $274.87M | +23.7% |
| 2024 | $222.15M | +35.8% |
| 2023 | $163.54M | +60.5% |
| 2022 | $101.92M | +1.7% |
| 2021 | $100.25M | +34.0% |
| 2020 | $74.81M | -25.2% |
| 2019 | $99.99M | +19.6% |
| 2018 | $83.58M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $70.57M | +33.7% | +2.3% |
| June 30, 2025 | $69.01M | +35.1% | +22.2% |
| March 31, 2025 | $56.47M | -1.7% | +7.0% |
| September 30, 2024 | $52.77M | +22.0% | +3.3% |
| June 30, 2024 | $51.07M | +33.8% | -11.1% |
| March 31, 2024 | $57.46M | +57.1% | +32.9% |
| September 30, 2023 | $43.25M | — | +13.3% |
| June 30, 2023 | $38.16M | — | +4.3% |
- Immunocore Holdings plc showed an increase of +23.7% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, Immunocore Holdings plc’s r&d expense has grown by 228.9% (from $83.58 million to $274.87 million).
- The most recent figure is from Immunocore Holdings plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: